|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9320 USD | -1.89% |
|
-2.91% | +34.55% |
| 07-16 | Elutia Agrees to Sell SimpliDerm for Up to $11 Million | MT |
| 07-15 | Cellution Biologics Llc agreed to acquire SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million. | CI |
| Market Cap | 42M 36.8M 34.16M 31.39M 59.15M 4.05B 60.02M 407M 159M 1.98B 158M 154M 6.85B | P/E 2026 * |
-1.58x | P/E 2027 * | -1.83x |
|---|---|---|---|---|---|
| Enterprise Value | 42M 36.8M 34.16M 31.39M 59.15M 4.05B 60.02M 407M 159M 1.98B 158M 154M 6.85B | EV / Sales 2026 * |
3.5x | EV / Sales 2027 * | 3.21x |
| Free-Float |
85.23% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Elutia Inc.
| 1 day | -1.89% | ||
| 1 week | -2.91% | ||
| Current month | -4.86% | ||
| 1 month | -6.80% | ||
| 3 months | -18.96% | ||
| 6 months | -7.72% | ||
| Current year | +34.55% |
| 1 week | 0.88 | 1 | |
| 1 month | 0.88 | 1.07 | |
| Current year | 0.6 | 1.38 | |
| 1 year | 0.5 | 2.5 | |
| 3 years | 0.5 | 5.24 | |
| 5 years | 0.5 | 9.76 | |
| 10 years | 0.5 | 18.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Operating Officer | 52 | - | |
Charles Mills
CEO | Chief Executive Officer | 54 | 2022-06-20 |
Matthew Ferguson
DFI | Director of Finance/CFO | 58 | 2020-09-27 |
| Director | Title | Age | Since |
|---|---|---|---|
Kevin Rakin
CHM | Chairman | 65 | 2015-10-31 |
Charles Mills
BRD | Director/Board Member | 54 | 2015-10-31 |
Brigid Makes
BRD | Director/Board Member | 70 | 2020-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/21/26 | Fiscal year | Founder | 53,010 | 0.1199% | ||
| 6/11/26 | Free | Director | 106,393 | 0.2407% | ||
| 6/11/26 | Free | Director | 106,393 | 0.2407% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.89% | -2.91% | -55.62% | -61.80% | 42M | ||
| -3.56% | -2.00% | +16.09% | -10.45% | 68.69B | ||
| -0.25% | +4.65% | +40.39% | +196.63% | 52.97B | ||
| -1.65% | +37.20% | +37.20% | +37.20% | 43.61B | ||
| -2.83% | -4.08% | -53.81% | -55.84% | 40.75B | ||
| -2.67% | +0.25% | +54.67% | -28.61% | 29.99B | ||
| -2.67% | -14.95% | +77.42% | -52.79% | 23.67B | ||
| -1.36% | +0.61% | +68.06% | +82.46% | 23.45B | ||
| +0.11% | +2.44% | +4.06% | +181.25% | 20.46B | ||
| -0.39% | +2.03% | +72.19% | +122.26% | 16.66B | ||
| Average | -1.70% | +1.02% | +26.07% | +41.03% | 32.03B | |
| Weighted average by Cap. | -1.94% | +1.22% | +28.18% | +45.62% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 12M 10.51M 9.76M 8.97M 16.9M 1.16B 17.15M 116M 45.51M 567M 45.05M 44.08M 1.96B | 13.1M 11.48M 10.66M 9.79M 18.45M 1.26B 18.72M 127M 49.68M 619M 49.18M 48.12M 2.14B |
| Net income | -25.4M -22.26M -20.66M -18.99M -35.78M -2.45B -36.3M -246M -96.33M -1.2B -95.35M -93.29M -4.14B | -22.4M -19.63M -18.22M -16.74M -31.55M -2.16B -32.01M -217M -84.96M -1.06B -84.09M -82.28M -3.65B |
| Net Debt | - | - |
Employees
26
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-22 | US$0.9320 | -1.89% | 87,425 |
| 26-07-21 | US$0.9500 | +2.14% | 49,769 |
| 26-07-20 | US$0.9301 | -2.09% | 26,367 |
| 26-07-17 | US$0.9500 | 0.00% | 251,437 |
| 26-07-16 | US$0.9500 | -1.03% | 831,926 |
Sell
Buy

Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9500USD
Average target price
5.000USD
Spread / Average Target
+426.32%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ELUT Stock
Select your edition
All financial news and data tailored to specific country editions

















